DOCSLIB.ORG

Protocol Use of Antidepressants and Risk of Hip/Femur Fracture

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protocol Use of Antidepressants and Risk of Hip/Femur Fracture WP2 Framework for pharmacoepidemiological studies WG1 Databases Study Protocol Use of Antidepressants and risk of hip/femur fracture. A methodological comparison across data sources and epidemiological design. Version: Final Nov 14, 2011 with Amendment 5 22 Jan , 2014 PROTECT WP2_ Final protocol_ Antidep_Hip 14Nov2011_Amend5_22Jan2014 Page 1 of 80 WG1 Drug AE group Name Role Gardarsdottir, Helga 1,2 Protocol lead Marieke De Bruin 1 Protocol backup Liset van Dijk 1,3 Protocol reviewer Montserrat Miret 4 Protocol reviewer Frank de Vries 1 Protocol reviewer Marietta Rottenkolber 5 Database 1 (Bavaria) lead Joerg Hasford 5 Database 1 (Bavaria) backup Consuelo Huerta 6 Database 2 (Bifap) lead Miguel Gil 6 Database 2 (Bifap) backup Ulrik Hesse7 Database 3 (DKMA) lead Frank de Vries1 Database 3 (DKMA) backup Edmond Ng /Jenny Campbell78 Database 4 (CPRD) lead/backup Olaf Klungel 1 Database 5 (Mondriaan) lead Liset van Dijk 1, 2 Database 5 (Mondriaan) backup Yolanda Alvarez 9 Database 6 (THIN) lead Ana Ruigomez 10 Database 6 (THIN) backup 1 Universiteit Utrecht, Utrecht, The Netherlands (UU) 2 University Medical Center Utrecht, Utrecht, The Netherlands (UU) 3 Netherlands Institute for Healthcare Research, Utrecht, The Netherlands (NIVEL) 4 Merck KGaA, Geneva, Switzerland (ME) 5 Ludwig-Maximilians-Universität-München, Munich, Germany (LMU- Muenchen) 6 Agencia Espanola de Medicamentos y Productos Sanitarios, Madrid, Spain (AEMPS) 7 Lægemiddelstyrelsen (Danish Medicines Agency), Copenhagen, Denmark (DKMA) 8 Clinical Practice Research Datalink, London, United Kingdom (CPRD) 9 European Medicines Agency, London, United Kingdom (EMA) 10 Fundación Centro Español de Investigación Farmacoepidemiológica, Madrid, Spain (CEIFE) PROTECT WP2_ Final protocol_ Antidep_Hip 14Nov2011_Amend5_22Jan2014 Page 2 of 80 Content 1 Context of the studies and objective ............................................................................................................ 66 2 Background.................................................................................................................................................. 66 3 Objectives .................................................................................................................................................... 66 4 Methods ....................................................................................................................................................... 66 4.1 Data sources ....................................................................................................................................... 66 4.2 The Health Improvement Network (THIN) ....................................................................................... 66 4.3 Mondriaan .......................................................................................................................................... 77 4.4 BIFAP ................................................................................................................................................ 77 4.5 Bavaria database ................................................................................................................................ 77 4.6 National Databases (Denmark) .......................................................................................................... 77 4.7 Clinical Practice Research Datalink (UK).......................................................................................... 88 4.8 Period of valid data collection ............................................................................................................ 88 4.8.1 THIN/Mondriaan/BIFAP ................................................................................................................... 88 4.8.2 Bavarian claims .................................................................................................................................. 99 5 Study Designs .............................................................................................................................................. 99 5.1 Descriptive studies ............................................................................................................................. 99 5.1.1 Study population and period .............................................................................................................. 99 5.1.2 Exposure description .......................................................................................................................... 99 5.1.3 Outcome description ...................................................................................................................... 1111 5.2 Analytical studies ........................................................................................................................... 1212 5.2.1 Study population and study period ................................................................................................. 1212 5.2.2 Outcome definition ........................................................................................................................ 1414 5.2.3 Exposure definition ........................................................................................................................ 1414 5.2.4 Potential confounders ..................................................................................................................... 1515 5.2.5 Analysis ......................................................................................................................................... 1616 5.3 Cohort ............................................................................................................................................ 1616 5.3.1 Follow-up ....................................................................................................................................... 1616 5.3.2 Analysis ......................................................................................................................................... 1717 5.4 Nested case-control ........................................................................................................................ 1717 5.4.1 Case definition ............................................................................................................................... 1717 5.4.2 Selection of controls....................................................................................................................... 1818 5.4.3 Confounders ................................................................................................................................... 1919 5.4.4 Analysis ......................................................................................................................................... 1919 5.5 Case-crossover ............................................................................................................................... 1919 5.5.1 Study population ............................................................................................................................ 1919 5.5.2 Case and control dates .................................................................................................................... 2020 5.5.1 Exposure definition ........................................................................................................................ 2020 5.5.2 Confounders ................................................................................................................................... 2020 5.5.3 Analysis ......................................................................................................................................... 2121 5.6 Self-controlled-case-series (SCCS) ................................................................................................ 2121 5.6.1 Study population ............................................................................................................................ 2121 5.6.2 Exposure definition ........................................................................................................................ 2222 5.6.1 Outcome definition ........................................................................................................................ 2323 5.6.2 Confounders ................................................................................................................................... 2323 5.6.3 Analysis ......................................................................................................................................... 2323 5.6.3.1 Sensitivity Analysis ......................................................................................................... 2424 6 Limitations ............................................................................................................................................... 2525 7 References ............................................................................................................................................... 2525 8 Annexes ................................................................................................................................................... 2727 8.1 Annex I codes for exposure and outcome ...................................................................................... 2727 8.1.1 List of Antidepressants, ATC codes and DDD ............................................................................. 2727 8.1.2
Load more

Recommended publications
  • Additions and Deletions to the Drug Product List
    Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690
    [Show full text]
  • Fosavance, INN-Alendronic Acid and Colecalciferol
    EMA/175858/2015 EMEA/H/C/000619 EPAR summary for the public Fosavance alendronic acid and colecalciferol This is a summary of the European public assessment report (EPAR) for Fosavance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Fosavance. What is Fosavance? Fosavance is a medicine that contains two active substances: alendronic acid and colecalciferol (vitamin D3). It is available as tablets (70 mg alendronic acid and 2,800 international units [IU] colecalciferol; 70 mg alendronic acid and 5,600 IU colecalciferol). What is Fosavance used for? Fosavance (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of low vitamin D levels. Fosavance 70 mg/5,600 IU is for use in patients who are not taking vitamin D supplements. Fosavance reduces the risk of fractures (broken bones) in the spine and the hip. The medicine can only be obtained with a prescription. How is Fosavance used? The recommended dose of Fosavance is one tablet once a week. It is intended for long-term use. The patient must take the tablet with a full glass of water (but not mineral water), at least 30 minutes before any food, drink or other medicines (including antacids, calcium supplements and vitamins). To avoid irritation of the oesophagus (the tube that leads from the mouth to the stomach), the patient should not lie down until after their first food of the day, which should be at least 30 minutes after taking the tablet.
    [Show full text]
  • LGM-Pharma-Regulatory-1527671011
    Pipeline Products List Specialty Portfolio Updated Q2 2018 Updated Q2 2018 See below list of newly approved API’s, samples are readily available for your R&D requirements: Inhalation Ophthalmic Transdermal Sublingual Abaloparatide Defibrotide Sodium Liraglutide Rituximab Abciximab Deforolimus Lixisenatide Rivastigmine Aclidinium Bromide Azelastine HCl Agomelatine Alprazolam Abemaciclib Delafloxacin Lumacaftor Rivastigmine Hydrogen Tartrate Beclomethasone Dipropionate Azithromycin Amlodipine Aripiprazole Acalabrutinib Denosumab Matuzumab Rizatriptan Benzoate Budesonide Besifloxacin HCl Apomorphine Eletriptan HBr Aclidinium Bromide Desmopressin Acetate Meloxicam Rocuronium Bromide Adalimumab Difluprednate Memantine Hydrochloride Rolapitant Flunisolide Bimatoprost Clonidine Epinephrine Aflibercept Dinoprost Tromethamine Micafungin Romidepsin Fluticasone Furoate Brimonidine Tartrate Dextromethorphan Ergotamine Tartrate Agomelatine Dolasetron Mesylate Mitomycin C Romosozumab Fluticasone Propionate Bromfenac Sodium Diclofenac Levocetrizine DiHCl Albiglutide Donepezil Hydrochloride Mometasone Furoate Rotigotine Formoterol Fumarate Cyclosporine Donepezil Meclizine Alectinib Dorzolamide Hydrochloride Montelukast Sodium Rucaparib Iloprost Dexamethasone Valerate Estradiol Melatonin Alemtuzumab Doxercalciferol Moxifloxacin Hydrochloride Sacubitril Alirocumab Doxorubicin Hydrochloride Mycophenolate Mofetil Salmeterol Xinafoate Indacaterol Maleate Difluprednate Fingolimod Meloxicam Amphotericin B Dulaglutide Naldemedine Secukinumab Levalbuterol Dorzolamide
    [Show full text]
  • Adrovance, INN-Alendronic Acid
    EMA/194587/2011 EMEA/H/C/000759 EPAR summary for the public Adrovance alendronic acid / colecalciferol This is a summary of the European public assessment report (EPAR) for Adrovance. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adrovance. What is Adrovance? Adrovance is a medicine that contains two active substances: alendronic acid and colecalciferol (vitamin D3). It is available as white tablets (capsule-shaped: 70 mg alendronic acid and 2,800 international units [IU] colecalciferol; rectangular: 70 mg alendronic acid and 5,600 IU colecalciferol). What is Adrovance used for? Adrovance (containing either 2,800 or 5,600 IU colecalciferol) is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and are at risk of low vitamin D levels. Adrovance 70 mg/5,600 IU is for use in patients who are not taking vitamin D supplements. Adrovance reduces the risk of broken bones in the spine and the hip. The medicine can only be obtained with a prescription. How is Adrovance used? The recommended dose of Adrovance is one tablet once a week. It is intended for long-term use. The patient must take the tablet with a full glass of water (but not mineral water), at least 30 minutes before any food, drink or other medicines (including antacids, calcium supplements and vitamins). To avoid irritation of the oesophagus (gullet), the patient should not lie down until after their first food of the day, which should be at least 30 minutes after taking the tablet.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Imidazoline Antihypertensive Drugs: Selective I1-Imidazoline Receptors Activation K
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by FarFar - Repository of the Faculty of Pharmacy, University of Belgrade REVIEW Imidazoline Antihypertensive Drugs: Selective I1-Imidazoline Receptors Activation K. Nikolic & D. Agbaba Faculty of Pharmacy, Institute of Pharmaceutical Chemistry, University of Belgrade, Vojvode Stepe, Belgrade, Serbia Keywords SUMMARY α2-Adrenergic receptors; Centrally acting antihypertensives; Clonidine; Hypertension; Involvement of imidazoline receptors (IR) in the regulation of vasomotor tone as well as in Imidazoline receptors; Rilmenidine. the mechanism of action of some centrally acting antihypertensives has received tremen- dous attention. To date, pharmacological studies have allowed the characterization of three Correspondence main imidazoline receptor classes, the I1-imidazoline receptor which is involved in central K. Nikolic, Faculty of Pharmacy, Institute of inhibition of sympathetic tone to lower blood pressure, the I2-imidazoline receptor which Pharmaceutical Chemistry, University of is an allosteric binding site of monoamine oxidase B (MAO-B), and the I3-imidazoline re- Belgrade, Vojvode Stepe 450, 11000 Belgrade, ceptor which regulates insulin secretion from pancreatic β-cells. All three imidazoline re- Serbia. ceptors represent important targets for cardiovascular research. The hypotensive effect of + Tel: 381-63-84-30-677; clonidine-like centrally acting antihypertensives was attributed both to α2-adrenergic re- + Fax: 381-11-3974-349; ceptors and nonadrenergic I1-imidazoline receptors, whereas their sedative action involves E-mail: [email protected] activation of only α2-adrenergic receptors located in the locus coeruleus. Since more selec- tive I1-imidazoline receptors ligands reduced incidence of typical side effects of other cen- trally acting antihypertensives, there is significant interest in developing new agents with higher selectivity and affinity for I1-imidazoline receptors.
    [Show full text]
  • Hydantoin and Succinimide-Substituted
    (1 9) J Eur°Pean Patent Office <*S Office europeen des brevets (11) EP 0 533 243 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) int. CI.6: C07D 401/1 2, C07D 471/10, of the grant of the patent: A61 K 31/445 Q07D 401 /1 4 17,2,997 Buiietin 1997/51 // (C07D471/1 0, 235:00, (21) Application number: 92202723.0 221:00) (22) Date of filing: 08.09.1992 (54) Hydantoin and succinimide-substituted spiroindanylcamphorsulfonyl derivatives Hydantoin und Succinimid-substituierte Spiroindanylcamphorsulfonyl als Oxytocin-Antagonisten Derives de spiroindanylcamphorsulfonyl substitues par un radical hydantoine ou succinimide comme antagonists d'oxytocine (84) Designated Contracting States: (74) Representative: CH DE FR GB IT LI NL Thompson, John Dr. et al Merck & Co., Inc. (30) Priority: 16.09.1991 US 760416 European Patent Department Terlings Park (43) Date of publication of application: Eastwick Road 24.03.1993 Bulletin 1993/12 Harlow, Essex CM20 2QR (GB) (73) Proprietor: Merck & Co., Inc. (56) References cited: Rahway New Jersey 07065-0900 (US) EP-A- 0 444 945 EP-A- 0 445 974 EP-A- 0 450 761 EP-A- 0 486 280 (72) Inventors: US-A- 3 654 287 • Gilbert, Kevin Bally, PA 19503 (US) • EP-A- 0 444 945 • Williams, Peter D. • EP-A- 0 445 974 Harleysville, PA 19438 (US) • EP-A- 0 450 761 • Hobbs, Doug W. • EP-A- 0 486 280 Lansdale, PA 19446 (US) • US-A- 3 654 287 • Evans, Ben E. Lansdale, PA 19446 (US) Remarks: • Veber, Daniel F. The file contains technical information submitted Ambler, PA 19002 (US) after the application was filed and not included in this specification CO CO CM CO CO Note: Within nine months from the publication of the mention of the grant of the European patent, give IO any person may notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • Protocol Supplementary
    Optimal Pharmacological Management and Prevention of Glucocorticoid-Induced Osteoporosis (GIOP) Protocol for a Systematic Review and Network Meta-Analysis Supplementary Materials: Sample Search Strategy Supplementary 1: MEDLINE Search Strategy Database: OVID Medline Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present Line 1 exp Osteoporosis/ 2 osteoporos?s.ti,ab,kf. 3 Bone Diseases, Metabolic/ 4 osteop?eni*.ti,ab,kf. 5 Bone Diseases/ 6 exp Bone Resorption/ 7 malabsorption.ti,ab,kf. 8 Bone Density/ 9 BMD.ti,ab,kf. 10 exp Fractures, Bone/ 11 fracture*.ti,ab,kf. 12 (bone* adj2 (loss* or disease* or resorption* or densit* or content* or fragil* or mass* or demineral* or decalcif* or calcif* or strength*)).ti,ab,kf. 13 osteomalacia.ti,ab,kf. 14 or/1-13 15 exp Glucocorticoids/ 16 exp Steroids/ 17 (glucocorticoid* or steroid* or prednisone or prednisolone or hydrocortisone or cortisone or triamcinolone or dexamethasone or betamethasone or methylprednisolone).ti,ab,kf. 18 or/15-17 19 14 and 18 20 ((glucocorticoid-induced or glucosteroid-induced or corticosteroid-induced or glucocorticosteroid-induced) adj1 osteoporos?s).ti,ab,kf. 21 19 or 20 22 exp Diphosphonates/ 23 (bisphosphon* or diphosphon*).ti,ab,kf. 24 exp organophosphates/ or organophosphonates/ 25 (organophosphate* or organophosphonate*).ti,ab,kf. 26 (alendronate or alendronic acid or Fosamax or Binosto or Denfos or Fosagen or Lendrate).ti,ab,kf. 27 (Densidron or Adrovance or Alenotop or Alned or Dronat or Durost or Fixopan or Forosa or Fosval or Huesobone or Ostemax or Oseolen or Arendal or Beenos or Berlex or Fosalen or Fosmin or Fostolin or Fosavance).ti,ab,kf.
    [Show full text]
  • Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds
    Syracuse University SURFACE Syracuse University Honors Program Capstone Syracuse University Honors Program Capstone Projects Projects Spring 5-1-2012 Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds Seungmo Suh Follow this and additional works at: https://surface.syr.edu/honors_capstone Part of the Biochemistry Commons Recommended Citation Suh, Seungmo, "Synthesis and Structural Studies of Calcium and Magnesium Diphosphonate Compounds" (2012). Syracuse University Honors Program Capstone Projects. 151. https://surface.syr.edu/honors_capstone/151 This Honors Capstone Project is brought to you for free and open access by the Syracuse University Honors Program Capstone Projects at SURFACE. It has been accepted for inclusion in Syracuse University Honors Program Capstone Projects by an authorized administrator of SURFACE. For more information, please contact [email protected]. 1 Chapter 1: Background 1.1 Introduction The chemistry of transition metal phosphonates has enormous potential and diverse applications such as gas separation, gas storage or catalyst systems which have been explored in detail.1-6 In contrast, analogous chemistry with the s- block elements has received only a little attention. Calcium was the priority element in our study due to its bioactive properties. Previous studies proved that phosphonates can possibly be used as bone repair materials. 1 The possible applications are only possible with structures with pores or channels for other molecules to enter. Thus, the control of the shape and
    [Show full text]
  • Comparison of the Anti-Inflammatory Effects of Cilomilast, Budesonide
    Ratcliffe and Dougall BMC Pharmacology and Toxicology 2012, 13:15 http://www.biomedcentral.com/2050-6511/13/15 RESEARCH ARTICLE Open Access Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages Marianne Jennifer Ratcliffe1* and Iain Gordon Dougall2 Abstract Chronic Obstructive Pulmonary Disease (COPD) is a disease characterized by a largely irreversible airflow obstruction and a persistent, excessive inflammatory response. Alveolar macrophages (AMs) are increased in the lungs of COPD patients, and act as orchestrators of the inflammatory response, releasing a range of mediators to coordinate recruitment and activation of leukocytes. Attempts to treat the inflammatory component of COPD with anti-inflammatory drugs such as steroids has met with limited success. In this study, we compared the ability of the phosphodiesterase IV (PDEIV) inhibitor Cilomilast, the steroid Budesonide, and the p38 mitogen activated protein kinase inhibitor BIRB-796 to inhibit tumour necrosis factor alpha (TNFα) and interleukin 6 (IL-6) releases from AMs isolated from COPD lung transplant tissue. All studies were carried out with appropriate ethical approval and written, informed consent was obtained from each subject. Cilomilast had little effect on cytokine release from AMs. There was considerable variability in the responsiveness of AMs to Budesonide, with a subset of AMs responding poorly to Budesonide. BIRB-796 inhibited TNFα release from all AM donors, including those that responded poorly to steroids. Treatment with BIRB-796 and Budesonide together gave an additive decrease in TNFa release. These results suggest that a p38 inhibitor may provide advantages over existing anti-inflammatory treatments for COPD, either as an add-on to existing therapy, or to treat patients who respond poorly to steroids.
    [Show full text]
  • Guidelines on Management of Osteoporosis, April 2011 (Updated 04/2012, 06/2013, 09/2013, 04/2014, 09/2014 and 02/2015)
    Hertfordshire Guidelines on Management of Osteoporosis, April 2011 (updated 04/2012, 06/2013, 09/2013, 04/2014, 09/2014 and 02/2015) Guidelines on Management of Osteoporosis Introduction These guidelines take into account recommendations from the DH Guidance on Falls and Fractures (Jul 2009), NICE Technology appraisals for Primary and Secondary Prevention (updated January 2011) and interpreted locally, National Osteoporosis Guideline Group (NOGG) and local decisions on choice of drug treatment. The recommendations in the guideline should be used to aid management decisions but do not replace the need for clinical judgement in the care of individual patients in clinical practice. Diagnosis of osteoporosis The diagnosis of osteoporosis relies on the quantitative assessment of bone mineral density (BMD), usually by central dual energy X-ray absorptiometry (DXA). BMD at the femoral neck provides the reference site. It is defined as a value for BMD 2.5 SD or more below the young female adult mean (T-score less than or equal to –2.5 SD). Severe osteoporosis (established osteoporosis) describes osteoporosis in the presence of 1 or more fragility fracture. Diagnostic thresholds differ from intervention thresholds for several reasons. Firstly, the fracture risk varies at different ages, even with the same T-score. Other factors that determine intervention thresholds include the presence of clinical risk factors and the cost and benefits of treatment. Investigation of osteoporosis The range of tests will depend on the severity of the disease, age at presentation and the presence or absence of fractures. The aims of the clinical history, physical examination and clinical tests are to: • Exclude diseases that mimic osteoporosis (e.g.
    [Show full text]
  • Alendronate, Etidronate, Risedronate, Raloxifene, Strontium Ranelate And
    Issue date: October 2008 (amended January 2010 and January 2011) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) NICE technology appraisal guidance 161 (amended) NICE technology appraisal guidance 161 (amended) Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended) Ordering information You can download the following documents from www.nice.org.uk/guidance/TA161 • The NICE guidance (this document). • A quick reference guide – the recommendations. • ‘Understanding NICE guidance’ – a summary for patients and carers. • Details of all the evidence that was looked at and other background information. For printed copies of the quick reference guide or ‘Understanding NICE guidance’, phone NICE publications on 0845 003 7783 or email [email protected] and quote: • N1725 (quick reference guide) • N1726 (’Understanding NICE guidance’). This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer. Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity.
    [Show full text]